Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data presented at the European Academy of Dermatology and Venereology (EADV) ...

4 Approximately half of patients with EGPA have adult-onset severe eosinophilic asthma (SEA) and often have sinus and nasal symptoms. 3,8,9 Fasenra is only the second biologic approved to treat this ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 15th annual Clarivate Pharmavision India conference. The 15th edition of ...

Biopharmaceuticals market Size. BURLINGAME, CA, UNITED STATES, September 11, 2024 /EINPresswire / -- The latest market intelligence report published by CMI ...

Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% ...

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations. Please note that if you subscribe to one of ...

they have not been transparent regarding biosimilars, so the FDA brought a new document to clarify these points in July 2024. First, it requires a thorough study of any changes made to the product, ...

SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Tanvex BioPharma ("Tanvex" or the "Company"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products ...

An AstraZeneca Plc unit settled a federal patent-infringement lawsuit with a Samsung Biologics Co. subsidiary after failing to block its biosimilar version of the $500,000-per-patient drug Soliris.

The API database is regularly updated to ensure the latest data is available to users. The next scheduled update is on: Upcoming API Database Update Date: 1st October 2024 Please note that this date ...

“We will continue to invest in research and development, line/capacity expansion related projects and capability enhancement projects, including biosimilars and biologics CMO. These investments ...

Indian drugmaker Biocon Ltd’s (BSE: 532523) biosimilars subsidiary Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson (NYSE: JNJ) subsidiaries (collectively known as ...